Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Metadata
Title
Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer
Authors
Chang F. Qu
Emma Y. Song
Yong Li
Syed M. A. Rizvi
Chand Raja
Ross Smith
Alfred Morgenstern
C. Apostolidis
Barry J. Allen
Publication date
01-11-2005
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 7/2005
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-005-5788-9

Other articles of this Issue 7/2005

Clinical & Experimental Metastasis 7/2005 Go to the issue

OriginalPaper

Endobronchial Metastases from Extrathoracic Malignancies

OriginalPaper

Metastasis Predictive Signature Profiles Pre-exist in Normal Tissues

OriginalPaper

MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate Cancer

OriginalPaper

Low-dose Methotrexate Inhibits Lung Metastasis and Lengthens Survival in Rat Osteosarcoma

OriginalPaper

Chromosomal Alterations in Lung Metastases of Colorectal Carcinomas: Associations with Tissue Specific Tumor Dissemination

OriginalPaper

Transforming Growth Factor-β1 Upregulates Transcription of α3 Integrin Gene in Hepatocellular Carcinoma Cells Via Ets-transcription Factor-binding Motif in the Promoter Region
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits